Gene therapy trial set to resume

Written byBob Grant

| 1 min read

The US Food and Drug Administration is allowing a controversial gene therapy trial to linkurl:resume,;http://ir.targen.com/phoenix.zhtml?c=84981&p=irol-newsArticle&ID=1080820&highlight= after the trial was linkurl:halted;http://www.the-scientist.com/news/display/53453/ when a 36-year-old participant died in July. The therapy, developed by Seattle based company Targeted Genetics, seeks to treat inflammatory arthritis, and is delivered via an adeno-associated viral (AAV) vector through an injection in the arthritic joint. At a meeting of the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) in September, RAC investigators linkurl:announced;http://www.the-scientist.com/news/display/53593/ preliminary autopsy results of the participant, Jolee Mohr, and suggested that a massive linkurl:fungal infection,;http://www.the-scientist.com/blog/display/53589/ and not the AAV treatment, caused her death. Investigators at the University of Chicago, where Mohr died, failed to find any of the AAV vector outside of Mohr's knee, where the virus was injected. According to a Targeted Genetics press release announcing the FDA decision, when Mohr was treated with the experimental AAV, she was taking other arthritis drugs that carry a risk for the fungal infection - called histoplasmosis - that killed her. The RAC will make the final results of its investigation public on December 3. The FDA lifted the hold on the clinical trial last week after reviewing data on the study's 127 participants and on Mohr's death. Before resuming the trial, however, Targeted Genetics must revise informed consent permissions for study participants to reflect the events surrounding Mohr's death and the results of the ensuing investigation. But some researchers are raising questions about the study's design, which allows patients to continue taking immune-suppressing drugs while receiving the experimental treatment, according to a linkurl:report;http://www.washingtonpost.com/wp-dyn/content/article/2007/11/25/AR2007112501229.html?hpid%3Dmoreheadlines&sub=new in __The Washington Post__. Kyle Hogarth, an intensive care unit doctor at the University of Chicago who treated Mohr and participated in the investigation of her death, told the __Post__: "I think they have a horrible design. It muddies the picture."

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

Gene therapy trial set to resume

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

Nergal Networks: Where Friendship Meets Infection

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Maximizing Lentivirus Recovery

Unraveling Complex Biology with Five-Dimensional Multiomics

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Seeing and Sorting with Confidence

Products

Product News

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

Agilent Announces the Enhanced 8850 Gas Chromatograph

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies